47 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Feb 24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
7:34pm
and patents expenses was due to the Company having completed the INM-755 Phase 2 clinical trial, offset by an increase in external contractor fees and personnel … fees, accounting and legal fees in the InMed segment offset by higher accounting and legal fees, and marketing expenses in the BayMedica segment
8-K
EX-99.1
ue7al3hb
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
1951 k5826w
16 May 23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
1:47pm
8-K
EX-99.1
th0798 xyjyyjcg
14 Nov 22
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
5:44pm
424B5
vnc227kufc pkyhuq39
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
7gifj w9oo
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
424B3
p75 mys6wsaj
25 Apr 22
Prospectus supplement
5:02pm
424B3
www70 jt1u0
7 Apr 22
Prospectus supplement
4:46pm